Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VIR Vir Biotechnology, Inc.

Trading 02-05 15:28:11 EST

6.93

-0.57

-7.67%

High7.50	Low6.90	Vol805.83K
Open7.35	D1 Closing7.50	Amplitude8.00%
Mkt Cap963.44M	Tradable Cap654.79M	Total Shares139.13M
T/O5.75M	T/O Rate0.85%	Tradable Shares94.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VIR","market":"US","secType":"STK","nameCN":"Vir Biotechnology, Inc.","latestPrice":6.925,"timestamp":1770323290614,"preClose":7.5,"halted":0,"volume":805830,"delay":0,"changeRate":-0.07666666666666669,"floatShares":94554590,"shares":139125032,"eps":-3.622804,"marketStatus":"Trading","change":-0.575,"latestTime":"02-05 15:28:11 EST","open":7.35,"high":7.5,"low":6.9,"amount":5751413.229654,"amplitude":0.08,"askPrice":6.93,"askSize":634,"bidPrice":6.92,"bidSize":1341,"shortable":3,"etf":0,"ttmEps":-3.622804,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770325200000},"marketStatusCode":2,"adr":0,"listingDate":1570766400000,"exchange":"NASDAQ","adjPreClose":7.5,"postHourTrading":{"tag":"盘后","latestPrice":7.5,"preClose":7.5,"latestTime":"19:55 EST","volume":17954,"amount":134664.72,"timestamp":1770252933135,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.590062,"impliedVol":1.2123,"impliedVolPercentile":0.9044},"requestUrl":"/m/hq/s/VIR","defaultTab":"news","newsList":[{"id":"2608354809","title":"Barclays Keeps Their Buy Rating on Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608354809","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608354809?lang=en_us&edition=fundamental","pubTime":"2026-02-04 17:16","pubTimestamp":1770196584,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on Vir Biotechnology, with a price target of $24.00. According to Ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-buy-rating-on-vir-biotechnology-vir-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-buy-rating-on-vir-biotechnology-vir-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIR"],"gpt_icon":0},{"id":"2608809814","title":"Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2608809814","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608809814?lang=en_us&edition=fundamental","pubTime":"2026-02-04 01:29","pubTimestamp":1770139759,"startTime":"0","endTime":"0","summary":"Vicki L. Sato, Director at Vir Biotechnology Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL4MXD29:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","VIR","BK4568","BK4585"],"gpt_icon":0},{"id":"2603636492","title":"Vir Biotechnology Reports Positive Data in Chronic Hepatitis Delta Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2603636492","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603636492?lang=en_us&edition=fundamental","pubTime":"2026-01-14 00:29","pubTimestamp":1768321746,"startTime":"0","endTime":"0","summary":"Vir Biotechnology  reported positive data from updated Phase 2 results in chronic hepatitis delta, showing that the combination of its investigational therapies tobevibart and elebsiran was well tolerated.The company said Monday in a statement that 88% of patients had no detectable hepatitis D virus in their blood at 96 weeks.Vir said it will present new Phase 1 data for VIR-5500, an experimental prostate-cancer therapy, at the American Society of Clinical Oncology's Genitourinary Cancers Symposium in February.The company ended 2025 with about $781 million in cash and investments, extending its cash runway into Q4 2027.Vir said it expects multiple clinical milestones in 2026, including initial topline data from its Phase 3 chronic hepatitis delta program.Vir shares rose 1.6% in recent Tuesday trading.Price: 6.02, Change: +0.09, Percent Change: +1.60","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4568","BK4585","VIR","BK4535"],"gpt_icon":0},{"id":"2603635757","title":"H.C. Wainwright says Vir’s SOLSTICE 96-week data reinforces best-in-class","url":"https://stock-news.laohu8.com/highlight/detail?id=2603635757","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603635757?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:45","pubTimestamp":1768319128,"startTime":"0","endTime":"0","summary":"H.C. Wainwright notes that Vir Biotechnology (VIR) released incremental Phase 2 SOLSTICE data, representing another major derisking event for the c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-says-virs-solstice-96-week-data-reinforces-best-in-class-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-says-virs-solstice-96-week-data-reinforces-best-in-class-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4535","BK4585","BK4139","VIR"],"gpt_icon":0},{"id":"2603635799","title":"Vir Biotechnology updates on chronic hepatitis delta and oncology programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603635799","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603635799?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:40","pubTimestamp":1768318813,"startTime":"0","endTime":"0","summary":"Ahead of Vir Biotechnology (VIR) presenting at the J.P. Morgan Healthcare Conference on Wednesday, January 14, at 3:45 p.m. PT, Vir Biotechnology y...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-updates-on-chronic-hepatitis-delta-and-oncology-programs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-updates-on-chronic-hepatitis-delta-and-oncology-programs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1548497426.USD","LU1668664300.SGD","LU0795875169.SGD","BK4516","BK4534","IE00BKVL7J92.USD","LU0106831901.USD","LU0528227936.USD","LU0795875086.SGD","LU1989772840.SGD","LU0971096721.USD","XBI","LU0314104364.USD","LU2347655156.SGD","BK4568","LU0158827781.USD","LU0098860793.USD","LU0882574139.USD","LU2028103732.USD","LU1791710582.SGD","LU1074936037.SGD","LU0106261372.USD","LU1162221912.USD","LU2089283258.USD","LU0006306889.USD","LU0234570918.USD","LU2357305700.SGD","LU0557290698.USD","LU1363072403.SGD","XLV","VIR","PT","LABU","BK4585","LU2023251221.USD","BK4504","BK4127","LU2089284900.SGD","LU1732799900.SGD","LU0158827948.USD","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU1244550221.USD","LU1244550494.USD","LU2111349929.HKD","JF","LU0912757837.SGD","LU1732800096.USD","LU1720051108.HKD","LU1244550577.SGD","LU0225283273.USD"],"gpt_icon":0},{"id":"2602510143","title":"BRIEF-Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510143","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510143?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:09","pubTimestamp":1768223377,"startTime":"0","endTime":"0","summary":"BRIEF-Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical MilestonesJan 12 (Reuters) - Vir Biotechnology Inc VIR.O:VIR BIOTECHNOLOGY PROVIDES","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUABGYS3X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","VIR","BK4568","BK4139","BK4585"],"gpt_icon":0},{"id":"2602310510","title":"Vir Biotechnology Reports 88% Undetectable HDV RNA at 96 Weeks with Tobevibart and Elebsiran Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2602310510","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602310510?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:02","pubTimestamp":1768222930,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. has announced new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta . The combination therapy of tobevibart, an investigational neutralizing monoclonal antibody, and elebsiran, an investigational small interfering RNA, demonstrated increased and sustained viral suppression of HDV RNA compared to the antibody alone in participants who have reached Week 96 of treatment. The combination therapy was well tolerated and achieved undetectable HDV RNA in 88% of evaluable participants at 96 weeks. Additionally, safety and efficacy data from the Phase 1 trial of VIR-5500, Vir’s PSMA-targeted PRO-XTEN dual-masked T-cell engager being evaluated in prostate cancer, will be presented in an oral presentation at the 2026 American Society of Clinical Oncology  Genitourinary Cancers Symposium in February. The company also noted it will report initial topline data from its Phase 3 CHD program in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6YSddS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4535","VIR","BK4585"],"gpt_icon":0},{"id":"2602956510","title":"Vir Biotechnology Inc: Positive, Updated Phase 2 Solstice Data Showed Combination of Tobevibart and Elebsiran Is Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2602956510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602956510?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUABGYS3X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","VIR","BK4585","BK4568"],"gpt_icon":0},{"id":"2602170395","title":"Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602170395","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602170395?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUABGYS3X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VIR","BK4139","BK4585","BK4535","BK4568"],"gpt_icon":0},{"id":"2601837860","title":"Vir Biotechnology CEO to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601837860","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601837860?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:05","pubTimestamp":1767647140,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, where CEO Marianne De Backer is scheduled to present on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California. A live webcast of the presentation will be available on the Vir Biotechnology website and archived for 30 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbrmbh5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","BK4535","BK4585","VIR"],"gpt_icon":0},{"id":"2601319968","title":"Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601319968","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601319968?lang=en_us&edition=fundamental","pubTime":"2026-01-06 03:02","pubTimestamp":1767639770,"startTime":"0","endTime":"0","summary":"Vicki L. Sato, Director at Vir Biotechnology Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL6hGHvk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","VIR","BK4535","BK4585","BK4139"],"gpt_icon":0},{"id":"2595479056","title":"Vir Biotechnology Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2595479056","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595479056?lang=en_us&edition=fundamental","pubTime":"2025-12-30 21:43","pubTimestamp":1767102180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VIR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 30, 2025 08:43 ET (13:43 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4568","BK4585","BK4139","BK4535"],"gpt_icon":0},{"id":"2592995830","title":"Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2592995830","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592995830?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:06","pubTimestamp":1765922771,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc. has appointed Minnie Kuo as Chief Operating Officer, effective immediately. Kuo joined the company in September 2023 as Chief Development Officer and has over 20 years of experience in biotechnology and pharmaceuticals, with prior leadership roles at Vir Biotechnology, Nektar Therapeutics, and Gilead Sciences.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL3FFM7N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","BK4566","LU1839511570.USD","IE00BZ1G4Q59.USD","SG9999015945.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU0058720904.USD","VIR","LU2468319806.SGD","BK4585","LU1430594728.SGD","LU0320765992.SGD","LU1674673691.USD","IE00B19Z3B42.SGD","LU0823416689.USD","BK4535","BK4139","SG9999015952.SGD","BK4583","SG9999015986.USD","LU0114720955.EUR","LU2324357040.USD","BK4578","BK4568","LU0289739699.SGD","LU2089984988.USD","BK4007","SG9999015978.USD","LU1674673428.USD","BK4532","IE00BSNM7G36.USD","GILD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1585245621.USD","LU0109394709.USD","IE00B3T34201.USD","PLRX","LU0234570918.USD","NKTR","LU2087621335.USD","LU0882574055.USD","BK4550","LU1066051498.USD","LU1571399168.USD","LU1778281490.HKD","BK4588","IE0002270589.USD"],"gpt_icon":0},{"id":"2592937970","title":"Vir Biotechnology Grants Norgine Exclusive License for Hepatitis Delta Treatment in Europe, Australia, and New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2592937970","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592937970?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:06","pubTimestamp":1765919161,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. announced that it has granted Norgine Pharma UK Limited an exclusive commercial license for the combination of tobevibart and elebsiran, an investigational treatment for chronic hepatitis delta, in Europe, Australia, and New Zealand. Under the terms of the agreement, Vir Biotechnology will receive an initial reimbursement payment of EUR 55 million and is eligible for up to EUR 495 million in clinical, regulatory, and sales milestones, as well as tiered royalties on net sales in Norgine's licensed territory. Vir Biotechnology will retain commercialization rights for the products in the United States and other markets outside Greater China. The agreement also includes a global cost-sharing arrangement for ongoing clinical development, with Norgine contributing approximately 25% of future external costs related to the ECLIPSE registrational program. The transaction in certain jurisdictions is subject to regulatory approvals.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL5Kvb1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4585","BK4535","VIR"],"gpt_icon":0},{"id":"2592937210","title":"Vir Biotechnology Inc - Norgine to Contribute 25% of Eclipse Program Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2592937210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592937210?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:05","pubTimestamp":1765919100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8NTZF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4535","BK4139","BK4585","VIR"],"gpt_icon":0},{"id":"2592893724","title":"Vir Biotechnology- Expects Current Cash, Cash Equivalents and Investments Will Be Extended Into Q4 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2592893724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592893724?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:05","pubTimestamp":1765919100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8NTZF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","BK4585","VIR","BK4535"],"gpt_icon":0},{"id":"2592379599","title":"Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing Eclipse Clinical Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2592379599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592379599?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:05","pubTimestamp":1765919100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8NTZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","VIR","BK4535","BK4585","BK4139"],"gpt_icon":0},{"id":"2592214937","title":"Vir Biotechnology - to Receive EUR 55 Mln Initial Reimbursement Payment Upon Closing , EUR 495 Mln in Clinical, Regulatory and Sales Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2592214937","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592214937?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:05","pubTimestamp":1765919100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA8NTZF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VIR","BK4568","BK4139","BK4585","BK4535"],"gpt_icon":0},{"id":"2589332882","title":"Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589332882","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589332882?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:32","pubTimestamp":1765189975,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. ( NASDAQ:VIR ) shareholders may have reason to be concerned, as several insiders sold their...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-insiders-sold-us11m-of-shares-suggesting-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-insiders-sold-us11m-of-shares-suggesting-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4568","BK4585","BK4535","BK4139","VIR"],"gpt_icon":0},{"id":"2588060158","title":"Director Vicki L. Sato Reports Sale of Vir Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588060158","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588060158?lang=en_us&edition=fundamental","pubTime":"2025-12-03 08:48","pubTimestamp":1764722917,"startTime":"0","endTime":"0","summary":"Vicki L. Sato, Director at Vir Biotechnology Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL759zP9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Vicki L. Sato Reports Sale of Vir Biotechnology Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4568","BK4535","VIR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vir.bio","stockEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.2953},{"period":"3month","weight":0.4648},{"period":"6month","weight":0.7442},{"period":"1year","weight":-0.2264},{"period":"ytd","weight":0.2438}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.442895},{"month":2,"riseRate":0.428571,"avgChangeRate":0.033205},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.121524},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.08783},{"month":5,"riseRate":0.666667,"avgChangeRate":0.058008},{"month":6,"riseRate":0.5,"avgChangeRate":0.020036},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.044477},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.0277},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.115495},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03118},{"month":11,"riseRate":0.857143,"avgChangeRate":0.105555},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.058058}],"exchange":"NASDAQ","name":"Vir Biotechnology, Inc.","nameEN":"Vir Biotechnology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vir Biotechnology, Inc.,VIR,Vir Biotechnology, Inc.股票,Vir Biotechnology, Inc.股票老虎,Vir Biotechnology, Inc.股票老虎国际,Vir Biotechnology, Inc.行情,Vir Biotechnology, Inc.股票行情,Vir Biotechnology, Inc.股价,Vir Biotechnology, Inc.股市,Vir Biotechnology, Inc.股票价格,Vir Biotechnology, Inc.股票交易,Vir Biotechnology, Inc.股票购买,Vir Biotechnology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}